Resistance Effectiveness Inflammatory Bowel Diseases Colon cancer Eradication DNA methylation IL12 Colectomy Disease Progression Acceptability PCR MALT Neoadjuvant chemotherapy Dysbiose Screening Heart disease risk factors Clinical trial Colonic epithelial primary cells Primary sclerosing cholangitis Cell adhesion Methylation Thérapie ciblée Venous thromboembolism Bactéries Inhibitor Kidney diseases Méthylation Gene methylation Parvimonas micra Fecal microbiota Dysbiosis Bacteria Patients experience Inflammatory bowel disease Over 80s 18 FDG-PET/CT Ustekinumab Epigénétiques Clinical guidelines Upper gastrointestinal tract MICROBIOTA Drug Cancer Rituximab Stricture Microbiota Safety Crohn’s disease Algorithm MORTALITY Contraindication Consensus Anti-TNF Colon Disability T1118 translocation Tuberculosis Colorectal cancer Crohn's disease Original Article Clinical Ulcerative colitis Gene expression MARKER Gènes Eligibility Immune cells Immunosuppressant Tailored therapy Therapeutics Maintenance therapy IBD Rituximab plus chlorambucil Inflammatory bowel diseases Microbiote Helicobacter pylori Genes Survival Disease progression CARCINOGENESIS Patient-reported outcome Endoscopic treatment Surgery Monitoring RISK Inclusion Cost effectiveness COLON-CANCER Anti-TNF agents HIV Vedolizumab Résistance Intestinal crypts Alkylating agents Biologics IL23 Biomarker Colorectal cancer Colibactin and lipids Epigenetics DNA METHYLATION Small molecules